Abstract
The International Consultation on Sexual Medicine defined erectile dysfunction (ED) as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual performance. A 3-month minimum duration is accepted for establishment of the diagnosis (Recommendations of the 1st International Consultation on Erectile Dysfunction Paris, France; Health Publications Ltd, 2010). The introduction of phosphodiesterase inhibitors has greatly changed the face of sexual medicine. Prior to this, sexual issues were shrouded in mystery and ignominy. Ancient cultures have all described sexual problems. Treatments in the form of herbs, spices, tonics, potions, mixtures, magic spells, and surgery have all been presented as remedies. Not until the past 30–40 years have we been able to understand and treat sexual issues commendably. That spirit continues today as we continue to investigate the finer points of erectile dysfunction management and turn our attention to address premature ejaculation, disorders of orgasm, hypogonadism, and female sexual dysfunction.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sturgill MG, Grasing KW, Rosen RC, et al. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc Pharmacol. 1997;29:697–703.
Piletz JE, Segraves KB, Feng YZ, Maguire E, Dunger B, Halaris A. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire. J Sex Marital Ther. 1998;24:43–54.
Guay AT, Spark RF, Jacobson J, Murray FT, Geisser ME. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res. 2002;14:25–31.
Pushkar D, Segal AS, Bagaev AG, Nosovitskii PB. Yohimbine in the treatment of erectile dysfunction. Urologiia. 2002;6:34–7.
Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993;22:22–6.
Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987;37:215–20.
De Smet PA, Smeets OS. Potential risks of health food products containing yohimbe extracts. BMJ. 1994;309:958.
Kunelius P, Hakkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology. 1997;49:441–4.
Teloken C, Rhoden EL, Sogari P, Dambros M, Souto CA. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol. 1998;159:122–4.
Vogt HJ, Brandl P, Kockott G, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res. 1997;9:155–61.
Pittler MH, Ernst E. Trials have shown yohimbine is effective for erectile dysfunction. BMJ. 1998;317:478.
Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159:433–6.
Himeno E, Ohyagi Y, Ma L, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011;69:248–56.
Lal S, Tesfaye Y, Thavundayil JX, et al. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:329–39.
Lal S, Ackman D, Thavundayil JX, Kiely ME, Etienne P. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1984;8:695–9.
Lal S, Laryea E, Thavundayil JX, et al. Apomorphine-induced penile tumescence in impotent patients--preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11:235–42.
Heaton JP, Morales A, Adams MA, Johnston B, El-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45:200–6.
Hsieh GC, Hollingsworth PR, Martino B, et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther. 2004;308:330–8.
Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26:232–8.
Gancher ST, Bennett W, English J. Studies of renal function in animals chronically treated with apomorphine. Res Commun Chem Pathol Pharmacol. 1989;66:163–6.
Pfeiffer RF, Gutmann L, Hull Jr KL, Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:93–100.
Gontero P, D'Antonio R, Pretti G, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res. 2005;17:80–5.
Pavone C, Curto F, Anello G, Serretta V, Almasio PL, Pavone-Macaluso M. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol. 2004;172:2347–9.
Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol. 1998;81:122–7.
Krege S, Goepel M, Sperling H, Michel MC. Affinity of trazodone for human penile alpha1-andalpha2-adrenoceptors. BJU Int. 2000;85:959–61.
Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003;92:441–6.
Kurt U, Ozkardes H, Altug U, Germiyanoglu C, Gurdal M, Erol D. The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol. 1994;152:407–9.
Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology. 1994;44:732–6.
Stryjer R, Spivak B, Strous RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009;32:82–4.
Taneja R. A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. J Sex Med. 2007;4:1136–41.
Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191–236.
Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53:417–50.
Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res. 2001;13 Suppl 3:S8–17.
Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153–65.
Clement P, Giuliano F. Anatomy and physiology of genital organs—men. Handb Clin Neurol. 2015;130:19–37.
Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32:379–95. v.
Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod. 1995;52:485–9.
Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47–52.
Sung BJ, Hwang KY, Jeon YH, et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003;425:98–102.
Wallis RM. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nihon Yakurigaku Zasshi. 1999;114 Suppl 1:22P–6.
Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453–9.
Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol. 2003;10 Suppl 1:12–6.
Staff P, editor. (2015). Physicians’ desk reference. 69th ed. PDR Network; 2015.
Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res. 2004;16 Suppl 1:S34–7.
Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43:260–7.
Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother. 2005;39:1286–95.
Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4:1315–30.
Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother. 2013;47:1312–20.
Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96:257–80.
Wang H, Yuan J, Hu X, Tao K, Liu J, Hu D. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin. 2014;30:1565–71.
Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63:902–12.
Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763–71.
Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–6.
Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192–9.
Hatzichristou D, Cuzin B, Martin-Morales A, et al. Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med. 2005;2:109–16.
Montorsi F, Althof SE. Partner responses to sildenafil citrate (viagra) treatment of erectile dysfunction. Urology. 2004;63:762–7.
Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43:521–31.
Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999;83:269–73.
Choi HK, Seong DH, Rha KH. Clinical efficacy of Korean red ginseng for erectile dysfunction. Int J Impot Res. 1995;7:181–6.
Hong B, Ji YH, Hong JH, Nam KY, Ahn TY. A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol. 2002;168:2070–3.
Jiang Z, Hu B, Wang J, et al. Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum. J Huazhong Univ Sci Technolog Med Sci. 2006;26:460–2.
Dell'Agli M, Galli GV, Dal Cero E, et al. Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008;71:1513–7.
Zhang ZB, Yang QT. The testosterone mimetic properties of icariin. Asian J Androl. 2006;8:601–5.
Laws KR, Sweetnam H, Kondel TK. Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis. Hum Psychopharmacol. 2012;27:527–33.
Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009:CD003120.
Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther. 1998;24:139–43.
Corazza O, Martinotti G, Santacroce R, et al. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba. Biomed Res Int. 2014;2014:841798.
Sikora RSM, Engelke B, et al. Randomized placebo-controlled study on the effects of oral treatment with gingko biloba extract in patients with erec-tile dysfunction. J Urol. 1998;159: 240A (Abstract #917).
Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol. 2002;17:279–84.
Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. 2004;19:545–8.
Kushner FG, Hand M, Smith Jr SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–306.
Clark AM, Catto S, Bowman G, Macintyre PD. Design matters in secondary prevention: individualization and supervised exercise improves the effectiveness of cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2011;18:761–9.
Rosen RC, Jackson G, Kostis JB. Erectile dysfunction and cardiac disease: recommendations of the second princeton conference. Curr Urol Rep. 2006;7:490–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bennett, N.E. (2016). Oral Prescription Therapy for Erectile Dysfunction. In: Köhler, T., McVary, K. (eds) Contemporary Treatment of Erectile Dysfunction. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-31587-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-31587-4_12
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-31585-0
Online ISBN: 978-3-319-31587-4
eBook Packages: MedicineMedicine (R0)